Twenty years of therapy for HIV-1 infection

被引：207

作者：

Pomerantz, RJ ^{[1
]}

Horn, DL ^{[1
]}

机构：

[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Human Virol & Biodef,Div Infect Dis & Environ, Philadelphia, PA 19107 USA

来源：

NATURE MEDICINE | 2003年 / 9卷 / 07期

关键词：

D O I：

10.1038/nm0703-867

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Antiretroviral therapy, where available, has transformed HIV-1 disease into a treatable and somewhat chronic infection. This article summarizes the accomplishments thus far and what lies ahead in our struggle to improve the treatment of, and possibly eliminate, HIV-1 infection.

引用

页码：867 / 873

页数：7

共 87 条

[11] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].

Carr, A ;

Samaras, K ;

Burton, S ;

Law, M ;

Freund, J ;

Chisholm, DJ ;

Cooper, DA .

AIDS, 1998, 12 (07) :F51-F58

[12] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].

Carr, A ;

Miller, J ;

Law, M ;

Cooper, DA .

AIDS, 2000, 14 (03) :F25-F32

[13] Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus Gag DNA Vaccines [J].

Caulfield, MJ ;

Wang, S ;

Smith, JG ;

Tobery, TW ;

Liu, X ;

Davies, ME ;

Casimiro, DR ;

Fu, TM ;

Simon, A ;

Evans, RK ;

Emini, EA ;

Shiver, J .

JOURNAL OF VIROLOGY, 2002, 76 (19) :10038-10043

[14] REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].

CONNOR, EM ;

SPERLING, RS ;

GELBER, R ;

KISELEV, P ;

SCOTT, G ;

OSULLIVAN, MJ ;

VANDYKE, R ;

BEY, M ;

SHEARER, W ;

JACOBSON, RL ;

JIMENEZ, E ;

ONEILL, E ;

BAZIN, B ;

DELFRAISSY, JF ;

CULNANE, M ;

COOMBS, R ;

ELKINS, M ;

MOYE, J ;

STRATTON, P ;

BALSLEY, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180

[15] Lopinavir/ritonavir - A review of its use in the management of HIV infection [J].

Cvetkovic, RS ;

Goa, KL .

DRUGS, 2003, 63 (08) :769-802

[16]

*DAIDS, 2003, N TRIZ COMP EF PLUS

[17]

De Clercq E, 2002, MED RES REV, V22, P531

[18] AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor [J].

Donzella, GA ;

Schols, D ;

Lin, SW ;

Esté, JA ;

Nagashima, KA ;

Maddon, PJ ;

Allaway, GP ;

Sakmar, TP ;

Henson, G ;

De Clercq, E ;

Moore, JP .

NATURE MEDICINE, 1998, 4 (01) :72-77

[19] Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy [J].

Dornadula, G ;

Zhang, H ;

VanUitert, B ;

Stern, J ;

Livornese, L ;

Ingerman, MJ ;

Witek, J ;

Kedanis, RJ ;

Natkin, J ;

DeSimone, J ;

Pomerantz, RJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (17) :1627-1632

[20] Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups [J].

Dornadula, G ;

Nunnari, G ;

Vanella, M ;

Roman, J ;

Babinchak, T ;

DeSimone, J ;

Stern, J ;

Braffman, M ;

Zhang, H ;

Pomerantz, RJ .

JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (11) :1682-1687

← 1 2 3 4 5 6 7 8 9 →